- Home
- PHUN vs QNCX Comparison
PHUN vs QNCX Comparison
Compare PHUN & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHUN
- QNCX
- Stock Information
- Founded
- PHUN 2009
- QNCX 2012
- Country
- PHUN United States
- QNCX United States
- Employees
- PHUN N/A
- QNCX N/A
- Industry
- PHUN EDP Services
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PHUN Technology
- QNCX Health Care
- Exchange
- PHUN Nasdaq
- QNCX Nasdaq
- Market Cap
- PHUN 62.1M
- QNCX 62.0M
- IPO Year
- PHUN N/A
- QNCX 2019
- Fundamental
- Price
- PHUN $2.77
- QNCX $1.41
- Analyst Decision
- PHUN Strong Buy
- QNCX Strong Buy
- Analyst Count
- PHUN 3
- QNCX 4
- Target Price
- PHUN $13.00
- QNCX $9.50
- AVG Volume (30 Days)
- PHUN 390.0K
- QNCX 119.3K
- Earning Date
- PHUN 05-08-2025
- QNCX 03-31-2025
- Dividend Yield
- PHUN N/A
- QNCX N/A
- EPS Growth
- PHUN N/A
- QNCX N/A
- EPS
- PHUN N/A
- QNCX N/A
- Revenue
- PHUN $3,537,000.00
- QNCX N/A
- Revenue This Year
- PHUN N/A
- QNCX N/A
- Revenue Next Year
- PHUN $93.33
- QNCX N/A
- P/E Ratio
- PHUN N/A
- QNCX N/A
- Revenue Growth
- PHUN N/A
- QNCX N/A
- 52 Week Low
- PHUN $2.70
- QNCX $0.51
- 52 Week High
- PHUN $14.60
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- PHUN 31.80
- QNCX 43.44
- Support Level
- PHUN $2.78
- QNCX $1.38
- Resistance Level
- PHUN $2.99
- QNCX $1.52
- Average True Range (ATR)
- PHUN 0.22
- QNCX 0.09
- MACD
- PHUN 0.01
- QNCX 0.01
- Stochastic Oscillator
- PHUN 8.00
- QNCX 40.37
About PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.